Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private pl ...